Drugs / LBP-EC01
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04191148 | Dec 2019 → Nov 2020 | urinary tract infection | Locus Biosciences | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05488340 | Jul 2022 → Jun 2026 overdue | urinary tract infection | Locus Biosciences | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LBP-EC01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04191148 ↗ |
| Modality | Other / unclassified | “crPhage cocktail” NCT04191148 ↗ |
| Route | Other | “dosed BID by intraurethral administration” NCT04191148 ↗ |